Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Industry

iMDx Pauses FDA De Novo Review of GraftAssureDx Kidney Rejection Test, Plans January Response

Insight Molecular Diagnostics says it will answer the FDA's request for more clinical validation information on its donor-derived cfDNA kit before the 21 January 2027 deadline.

16 Nov 2026 · Insight Molecular Diagnostics Inc. IMDX · Company news

Insight Molecular Diagnostics (iMDx) reported its third-quarter 2026 results on 16 November, with the status of its US regulatory submission for GraftAssureDx a central point. The company's headline revenue figure for the quarter was $559,000.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Insight Molecular Diagnostics Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More IndustryAll →